- Home
- VTLE vs AMLX Comparison
VTLE vs AMLX Comparison
Compare VTLE & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTLE
- AMLX
- Stock Information
- Founded
- VTLE 2006
- AMLX 2014
- Country
- VTLE United States
- AMLX United States
- Employees
- VTLE N/A
- AMLX N/A
- Industry
- VTLE
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- VTLE
- AMLX Health Care
- Exchange
- VTLE Nasdaq
- AMLX Nasdaq
- Market Cap
- VTLE 640.1M
- AMLX 684.6M
- IPO Year
- VTLE 2011
- AMLX 2022
- Fundamental
- Price
- VTLE $18.58
- AMLX $8.15
- Analyst Decision
- VTLE Hold
- AMLX Strong Buy
- Analyst Count
- VTLE 11
- AMLX 7
- Target Price
- VTLE $26.75
- AMLX $12.00
- AVG Volume (30 Days)
- VTLE 1.2M
- AMLX 2.2M
- Earning Date
- VTLE 08-06-2025
- AMLX 08-07-2025
- Dividend Yield
- VTLE N/A
- AMLX N/A
- EPS Growth
- VTLE N/A
- AMLX N/A
- EPS
- VTLE N/A
- AMLX N/A
- Revenue
- VTLE $1,982,155,000.00
- AMLX N/A
- Revenue This Year
- VTLE $3.16
- AMLX N/A
- Revenue Next Year
- VTLE N/A
- AMLX N/A
- P/E Ratio
- VTLE N/A
- AMLX N/A
- Revenue Growth
- VTLE 16.77
- AMLX N/A
- 52 Week Low
- VTLE $12.30
- AMLX $1.76
- 52 Week High
- VTLE $44.94
- AMLX $8.72
- Technical
- Relative Strength Index (RSI)
- VTLE 56.30
- AMLX 64.12
- Support Level
- VTLE $16.56
- AMLX $7.70
- Resistance Level
- VTLE $17.62
- AMLX $8.67
- Average True Range (ATR)
- VTLE 1.07
- AMLX 0.51
- MACD
- VTLE 0.12
- AMLX -0.02
- Stochastic Oscillator
- VTLE 83.59
- AMLX 73.55
About VTLE Vital Energy Inc. par value $0.01 per share
Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.